Avacta (AIM: AVCT) currently expects its existing cash resources to last into early Q1 2027 and is continuing discussions with potential partners for its next-generation assets.
Abingdon Health Official opening of manufacturing hub in the US
Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and provider of regulatory services for rapid diagnostic tests and med-tech, announces the official opening yesterday of its
Avacta Group Further Demonstration of Potential of AVA6103
Avacta Therapeutics (AIM: AVCT) has presented the design of its Phase 1 FOCUS-01 trial and updated preclinical data supporting AVA6103 in pancreatic ductal adenocarcinoma at the AACR Conference on Pancreatic
Avacta Reports Clinical Proof of Mechanism for AVA6103 in Phase 1 Trial
Avacta Therapeutics (AIM: AVCT) has reported clinical proof of mechanism for AVA6103, its next-generation pre|CISION® peptide-drug conjugate, from the ongoing Phase 1 FOCUS-01 trial.
Avacta Appoints Mats Blom to Board as Audit Committee Chair
Avacta Therapeutics (AIM: AVCT) has appointed experienced biotechnology finance executive Mats Blom to its Board of Directors, where he will also serve as Chair of the Audit Committee.
Avacta pays £2.61m bond instalment as debt falls to £12m
Avacta Therapeutics (AIM: AVCT) has settled an accelerated deferred convertible bond repayment of £2.613 million in cash, reducing the remaining principal under the facility to £12 million.
Avacta Awards CEO 13.4m Share Options at 69p as Clinical Pipeline Advances
Avacta (AIM: AVCT) has granted a substantial package of share options to its management team, including 13.4 million options to chief executive Christina Coughlin, as part of an incentive and
Avacta cuts convertible bond debt with £3.67m payment
Accelerated Amortized Payment of Convertible Bond Installment
Avacta Appoints Patrick Vink as Deputy Chairman
Avacta Therapeutics (AIM: AVCT) has appointed healthcare executive Dr Patrick Vink to its board as non-executive deputy chairman and senior independent director.
Avacta advances AVA6000 towards pivotal US trial
Avacta Therapeutics (AIM: AVCT) has secured a significant regulatory milestone after reaching an agreement with the US Food and Drug Administration on the pivotal trial design for its lead cancer
Shareholders give overwhelming support to Avacta proposals
Avacta Group PLC announced that all resolutions were passed at its Annual General Meeting, with overwhelming shareholder support for each proposal.
Avacta Extends Cash Runway as Clinical Pipeline Advances
Avacta Therapeutics (AIM: AVCT) has reported strong progress across its oncology pipeline in the first half of 2026, highlighting advances in both its clinical programmes and balance sheet ahead of